Neuronetics, Inc. (NASDAQ:STIM – Get Rating) SVP William Andrew Macan sold 16,046 shares of the stock in a transaction that occurred on Monday, January 23rd. The stock was sold at an average price of $5.96, for a total transaction of $95,634.16. Following the completion of the sale, the senior vice president now owns 338,719 shares of the company’s stock, valued at approximately $2,018,765.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Neuronetics Stock Up 1.0 %
Neuronetics stock opened at $5.89 on Wednesday. The company has a market capitalization of $160.33 million, a P/E ratio of -4.30 and a beta of 2.12. The firm’s fifty day simple moving average is $6.14 and its 200-day simple moving average is $4.47. The company has a current ratio of 4.02, a quick ratio of 3.68 and a debt-to-equity ratio of 0.43. Neuronetics, Inc. has a 1-year low of $1.98 and a 1-year high of $6.95.
Neuronetics (NASDAQ:STIM – Get Rating) last released its quarterly earnings results on Tuesday, November 8th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.16. The business had revenue of $16.50 million for the quarter, compared to the consensus estimate of $14.79 million. Neuronetics had a negative net margin of 58.85% and a negative return on equity of 49.80%. Sell-side analysts forecast that Neuronetics, Inc. will post -1.51 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of STIM. David J Yvars Group raised its holdings in Neuronetics by 46.1% in the 4th quarter. David J Yvars Group now owns 37,420 shares of the company’s stock worth $257,000 after acquiring an additional 11,800 shares during the period. Two Sigma Advisers LP raised its holdings in Neuronetics by 49.7% in the 3rd quarter. Two Sigma Advisers LP now owns 187,000 shares of the company’s stock worth $595,000 after acquiring an additional 62,100 shares during the period. Two Sigma Investments LP raised its holdings in Neuronetics by 267.2% in the 3rd quarter. Two Sigma Investments LP now owns 101,016 shares of the company’s stock worth $321,000 after acquiring an additional 73,508 shares during the period. Vanguard Group Inc. raised its holdings in Neuronetics by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,145,310 shares of the company’s stock worth $3,642,000 after acquiring an additional 11,102 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in Neuronetics by 66.1% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 19,100 shares of the company’s stock worth $61,000 after acquiring an additional 7,600 shares during the period. Institutional investors own 62.90% of the company’s stock.
Neuronetics Company Profile
Neuronetics, Inc commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients.
- Get a free copy of the StockNews.com research report on Neuronetics (STIM)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.